Caris Pathology

Caris Life Sciences is a leading precision medicine and 'TechBio' company that provides comprehensive molecular profiling for cancer patients. The company utilizes advanced technologies, including Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), and artificial intelligence (AI) to analyze DNA, RNA, and proteins, creating a 'molecular blueprint' to guide personalized treatment decisions. Caris has built one of the world's largest clinico-genomic databases and partners with over 100 biopharmaceutical companies to support drug development and clinical trials. Headquartered in Irving, Texas, the company went public in June 2025 and continues to innovate in early cancer detection and therapy selection through its proprietary AI platform, DEAN.